Related Experiment Videos
Cyclosporin A responsive chronic severe vesicular hand eczema
1Department of Dermatology, Gentofte Hospital, Copenhagen, Denmark.
Acta Dermato-Venereologica
|November 1, 1992
Summary
Cyclosporin A (CsA) offers significant relief for severe hand eczema unresponsive to other treatments. This immunosuppressant demonstrated rapid improvement, highlighting its potential therapeutic role.
Area of Science:
- Dermatology
- Immunosuppression
Background:
- Chronic vesicular hand eczema is often recalcitrant to standard treatments.
- Identifying effective therapies for severe cases remains a clinical challenge.
Observation:
- A patient with severe hand eczema experienced dramatic improvement within two weeks of initiating cyclosporin A (CsA) therapy at 5.0 mg/kg daily.
- The patient maintained remission with a reduced CsA dose of 2.5 mg/kg daily.
- Discontinuation of CsA due to elevated blood pressure led to rapid eczema recurrence.
Findings:
- Oral cyclosporin A (CsA) demonstrated significant efficacy in managing severe, treatment-resistant chronic vesicular hand eczema.
- The therapeutic effect of CsA was dose-dependent and reversible upon cessation.
Implications:
- Oral CsA should be considered as a viable treatment option for patients with severe hand eczema refractory to conventional immunosuppressive therapies.
- Further research into the long-term safety and efficacy of CsA in hand eczema is warranted.